Quality Improvement and Research in Neurology Using Electronic Medical Records

This study aims to improve care for common neurological conditions like brain tumors, epilepsy, migraine, and mild cognitive impairment. Researchers are using electronic medical records (EMR) at NorthShore University HealthSystem to find the most effective treatments. They are testing existing drugs such as lamotrigine, levetiracetam, and valproic acid for brain tumors and epilepsy; donepezil, rivastigmine, and memantine for mild cognitive impairment; and amitriptyline, propranolol, topiramate, sumatriptan, rizatriptan, and zolmitriptan for migraine. You may be able to join if you are 18 to 100 years old and have one of these conditions, along with others like concussion or Parkinson's disease, and are eligible for one of the tested treatments. Success will be measured by how long participants remain on their assigned treatment or avoid disability, depending on their condition. The current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 3300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for six months for migraine, and for one year for epilepsy and mild cognitive impairment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02670161

Quality Improvement and Practice Based Research in Neurology Using the EMR

Enrolling by Invitation
PHASE4Ages 18+InterventionalTreatment
Endeavor Health
~3,300 participants
Updated 2025-08-24 on ClinicalTrials.gov
What's tested:Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
survival free of discontinuation or alternative prevention drug (migraine trial)
Measured over six months
+2 more outcomes measured
Brain Tumors
Epilepsy
Migraine
Mild Cognitive Impairment
Concussion
Multiple Sclerosis
Neuropathy
Parkinson's
Restless Legs Syndrome
Stroke

NCT02670161

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • NorthShore University HealthSystem

    Evanston, Illinoisno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of brain tumors, epilepsy, migraine, mild cognitive impairment (concussion), mild traumatic brain injury, multiple sclerosis, neuropathy, Parkinson's disease, restless legs syndrome, and stroke.
Eligible to receive any of the three compared treatments according to FDA approval for the indication or off label use according to standard of care.
  • survival free of discontinuation or alternative prevention drug (migraine trial)six months
  • survival free of disability measured by FAQ score 9+ (memory trial)one year
  • survival free of discontinuation or alternative anti epileptic drug (epilepsy trial)one year